{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:09:07Z","timestamp":1777637347959,"version":"3.51.4"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Multiple Myeloma is a malignant hematologic disorder characterized by the abnormal proliferation of clonal plasma cells. Its pathogenesis involves a variety of complex factors, with particular attention given to the immune regulatory mechanisms within the tumor microenvironment (TME). Research indicates that the immunosuppressive microenvironment provides a protective barrier for the survival and progression of MM cells. In this context, regulatory T cells (Tregs), as key immunosuppressive cells within the TME, play a crucial role in the tumor immune tolerance network. Through interactions with various immune cells and tumor-associated factors, Tregs participate in the regulation of MM-related signaling pathways and mediate tumor angiogenesis, thereby promoting immune evasion of MM cells. This review aims to explore the specific roles and clinical significance of Tregs in the immune mechanisms of MM.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1830089","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:07:35Z","timestamp":1777442855000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The mechanisms of regulatory T cells in the immune microenvironment of multiple myeloma and clinical significance"],"prefix":"10.3389","volume":"17","author":[{"given":"Lijun","family":"Du","sequence":"first","affiliation":[{"name":"Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumeng","family":"Jiang","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaolin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological Malignancy by sub-type: a report from the haematological Malignancy research network","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-380410","article-title":"Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000167","article-title":"Idelalisib: targeting the Pi3 kinase pathway in non-Hodgkin lymphoma","volume":"22","author":"Sujobert","year":"2016","journal-title":"Cancer J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.599098","article-title":"Actors on the scene: immune cells in the myeloma niche","volume":"10","author":"Leone","year":"2020","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ni1179","article-title":"A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3","volume":"6","author":"Fontenot","year":"2005","journal-title":"Nat Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nri2785","article-title":"Foxp3+ regulatory T cells in the human immune system","volume":"10","author":"Sakaguchi","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3101","article-title":"Dysfunctional T regulatory cells in multiple myeloma","volume":"107","author":"Prabhala","year":"2006","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of Cd4+Cd25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160062","article-title":"Ctla-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of Cd80 and Cd86: a molecular basis for the cell-extrinsic function of Ctla-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the Gprc5dxcd3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-3192","article-title":"Targeting Cd38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/jci88169","article-title":"Blocking Ifnar1 inhibits multiple myeloma-driven Treg expansion and immunosuppression","volume":"128","author":"Kawano","year":"2018","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/frtra.2023.1149334","article-title":"Type I interferons augment regulatory T cell polarization in concert with ancillary cytokine signals","volume":"2","author":"Eskandari","year":"2023","journal-title":"Front Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"11593","DOI":"10.1038\/s41598-024-62298-3","article-title":"Treg-derived Tgf-B1 dampens cgas-sting signaling to downregulate the expression of class I Mhc complex in multiple myeloma","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.4.1783","article-title":"Cutting edge: contact-mediated suppression by Cd4+Cd25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism","volume":"174","author":"Gondek","year":"2005","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.3.1582","article-title":"Cd4+Cd25+ T regulatory cells suppress Nk cell-mediated immunotherapy of cancer","volume":"176","author":"Smyth","year":"2006","journal-title":"J Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042276","article-title":"Tgf-beta1 maintains suppressor function and Foxp3 expression in Cd4+Cd25+ regulatory T cells","volume":"201","author":"Marie","year":"2005","journal-title":"J Exp Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral Cd4+Cd25- naive T cells to Cd4+Cd25+ regulatory T cells by Tgf-beta induction of transcription factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"Stats in cancer inflammation and immunity: a leading role for Stat3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.200111","article-title":"Mechanisms of immune suppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine","volume":"10","author":"Yaseen","year":"2020","journal-title":"Open Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000610","article-title":"Conversion of Atp to adenosine by Cd39 and Cd73 in multiple myeloma can be successfully targeted together with adenosine receptor A2a blockade","volume":"8","author":"Yang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0605251103","article-title":"A2a adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901247","article-title":"A2a adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments","volume":"183","author":"Ohta","year":"2009","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-081646","article-title":"A2a receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells","volume":"111","author":"Zarek","year":"2008","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-14-0018","article-title":"Inhibition of Cd39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity","volume":"3","author":"Bastid","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0242-6","article-title":"April signaling via Taci mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications","volume":"33","author":"Tai","year":"2019","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/life14040461","article-title":"Role of immune cells and immunotherapy in multiple myeloma","volume":"14","author":"Radhakrishnan","year":"2024","journal-title":"Life (Basel)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.immuni.2007.11.016","article-title":"T helper 17 lineage differentiation is programmed by orphan nuclear receptors Ror alpha and Ror gamma","volume":"28","author":"Yang","year":"2008","journal-title":"Immunity"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/293479","article-title":"The role of regulatory T cells and Th17 cells in multiple myeloma","volume":"2012","author":"Braga","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","article-title":"Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy","volume":"58","author":"Diaz-Montero","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055818","article-title":"Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble Cd25 in Sokal high risk chronic myeloid leukemia","volume":"8","author":"Christiansson","year":"2013","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1102471","article-title":"The immune suppressive tumor microenvironment in multiple myeloma: the contribution of myeloid-derived suppressor cells","volume":"13","author":"Giannotta","year":"2022","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2016.04.002","article-title":"Myeloid-derived suppressor cells: the green light for myeloma immune escape","volume":"30","author":"Malek","year":"2016","journal-title":"Blood Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"G\u00f6rg\u00fcn","year":"2013","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02679-x","article-title":"Post-treatment improvement of Nk cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens","volume":"110","author":"Vela-Ojeda","year":"2019","journal-title":"Int J Hematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2022.03.012","article-title":"Prognostic role of the ratio of natural killer cells to regulatory T cells in patients with multiple myeloma treated with lenalidomide and dexamethasone","volume":"110","author":"Kim","year":"2022","journal-title":"Exp Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03879.x","article-title":"Anti-myeloma activity of natural killer lymphocytes","volume":"119","author":"Frohn","year":"2002","journal-title":"Br J Haematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051511","article-title":"Cd4+Cd25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner","volume":"202","author":"Ghiringhelli","year":"2005","journal-title":"J Exp Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/neuonc\/nop009","article-title":"Tgf-beta downregulates the activating receptor Nkg2d on Nk cells and Cd8+ T cells in glioma patients","volume":"12","author":"Crane","year":"2010","journal-title":"Neuro Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6248590","article-title":"Altered Nkp30, Nkp46, Nkg2d, and Dnam-1 expression on circulating Nk cells is associated with tumor progression in human gastric cancer","volume":"2018","author":"Han","year":"2018","journal-title":"J Immunol Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000015722","article-title":"Cd4+Cd25+Foxp3+ regulatory T cells suppress Nkg2d-mediated Nk cell cytotoxicity in peripheral blood","volume":"98","author":"Geng","year":"2019","journal-title":"Med (Balt)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020904","article-title":"Dendritic cell-based immunotherapy in multiple myeloma: challenges, opportunities, and future directions","volume":"23","author":"Verheye","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-12-2271","article-title":"Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via Icos costimulation of Foxp3(+) T-regulatory cells","volume":"72","author":"Conrad","year":"2012","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-623975","article-title":"Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from cd8+ t-cell killing","volume":"126","author":"Leone","year":"2015","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.135","article-title":"A novel agent sl-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells","volume":"31","author":"Ray","year":"2017","journal-title":"Leukemia"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0280-2","article-title":"Regulatory t cells mediate specific suppression by depleting peptide-mhc class ii from dendritic cells","volume":"20","author":"Akkaya","year":"2019","journal-title":"Nat Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.206.supp.96.04","article-title":"Treg-expressed ctla-4 depletes cd80\/cd86 by trogocytosis, releasing free pd-l1 on antigen-presenting cells","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2006.02362.x","article-title":"Cytotoxic t lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in cd4+ cd25+ regulatory t-cell-mediated suppression","volume":"118","author":"Oderup","year":"2006","journal-title":"Immunology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200324552","article-title":"Induction of foxp3-expressing regulatory cd4pos t cells by human mature autologous dendritic cells","volume":"34","author":"Verhasselt","year":"2004","journal-title":"Eur J Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050463","article-title":"Tumor cells convert immature myeloid dendritic cells into tgf-beta-secreting cells inducing cd4+cd25+ regulatory t cell proliferation","volume":"202","author":"Ghiringhelli","year":"2005","journal-title":"J Exp Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425093","article-title":"Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of tr1-like regulatory t cells","volume":"35","author":"Fiore","year":"2005","journal-title":"Eur J Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-220285","article-title":"Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis","volume":"114","author":"Zheng","year":"2009","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized m2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2018.02.009","article-title":"Infiltration of tumor associated macrophages in multiple myeloma and its clinical significance","volume":"39","author":"Gui","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory t cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019495","article-title":"Tumor-associated macrophages recruit ccr6+ regulatory t cells and promote the development of colorectal cancer via enhancing ccl20 production in mice","volume":"6","author":"Liu","year":"2011","journal-title":"PloS One"},{"key":"B65","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-016-0154-9","article-title":"Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, cd39- and cd73-dependent mechanism for tumor immune escape","volume":"4","author":"Montalb\u00e1n Del Barrio","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.04.001","article-title":"Tnfr1 signaling and ifn-gamma signaling determine whether t cells induce tumor dormancy or promote multistage carcinogenesis","volume":"13","author":"M\u00fcller-Hermelink","year":"2008","journal-title":"Cancer Cell"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80218-6","article-title":"Cd4+ t cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on ifn gamma receptor expression by nonhematopoietic cells","volume":"12","author":"Qin","year":"2000","journal-title":"Immunity"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.11.5931","article-title":"Cd4+\/cd25+ regulatory cells inhibit activation of tumor-primed cd4+ t cells with ifn-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination","volume":"171","author":"Casares","year":"2003","journal-title":"J Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/nature10169","article-title":"Tumour hypoxia promotes tolerance and angiogenesis via ccl28 and t(reg) cells","volume":"475","author":"Facciabene","year":"2011","journal-title":"Nature"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2016.03.021","article-title":"Advances on immunomodulatory drugs against multiple myeloma","volume":"37","author":"Wang","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.575","article-title":"The frequency of t regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma","volume":"106","author":"Giannopoulos","year":"2012","journal-title":"Br J Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of t regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.652106","article-title":"Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma","volume":"53","author":"Muthu Raja","year":"2012","journal-title":"Leuk Lymph"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.247","article-title":"Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of cd4+foxp3+ t cells","volume":"23","author":"Minnema","year":"2009","journal-title":"Leukemia"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2015.05.019","article-title":"Ex vivo evaluation of the effect of regulatory t cells on the anti-tumor activity of bortezomib in multiple myeloma","volume":"44","author":"Ercetin","year":"2016","journal-title":"Exp Hematol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.7534\/j.issn.1009-2137.2018.02.029","article-title":"Effect and clinical significance of bortezomib and thalidomide on the memory t cells subsets and regulatory t cells in peripheral blood of patients with multiple myeloma","volume":"26","author":"Shi","year":"2018","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03657-3","article-title":"Evaluation of regulatory t cells (tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome","volume":"98","author":"Hadjiaggelidou","year":"2019","journal-title":"Ann Hematol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.005017","article-title":"Treatment with bortezomib of human cd4+ t cells preserves natural regulatory t cells and allows the emergence of a distinct suppressor t-cell population","volume":"94","author":"Blanco","year":"2009","journal-title":"Haematologica"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-018-0096-7","article-title":"Deep sustained response to daratumumab monotherapy associated with t-cell expansion in triple refractory myeloma","volume":"7","author":"Usmani","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.2013750","article-title":"Structural and functional characterization of a monoclonal antibody blocking tigit","volume":"14","author":"Jeong","year":"2022","journal-title":"Mabs"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-230X(10)07001-6","article-title":"Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy","volume":"107","author":"Sharabi","year":"2010","journal-title":"Adv Cancer Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29918","article-title":"Mucin 1-specific active cancer immunotherapy with tecemotide (l-blp25) in patients with multiple myeloma: an exploratory study","volume":"10","author":"Rossmann","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2326-6066.cir-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000286","article-title":"Regulatory t-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study","volume":"8","author":"Derman","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.5152\/tjh.2011.26","article-title":"The correlation between t regulatory cells and autologous peripheral blood stem cell transplantation in multiple myeloma","volume":"28","author":"Er\u00e7etin","year":"2011","journal-title":"Turk J Haematol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.618610","article-title":"Increased immune-regulatory receptor expression on effector t cells as early indicators of relapse following autologous stem cell transplantation for multiple myeloma","volume":"12","author":"Lee","year":"2021","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1186\/s12967-025-07106-w","article-title":"Integrated clinical and single-cell profiling of bcma car-t therapy in relapsed\/refractory multiple myeloma","volume":"23","author":"Fang","year":"2025","journal-title":"J Transl Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-70867-5","article-title":"Timosaponin aiii enhances car-t cell potency and prevents relapse through impairing car-tregs","volume":"17","author":"Hou","year":"2026","journal-title":"Nat Commun"},{"key":"B92","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/nejmoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00186-8","article-title":"Mechanisms of resistance against t-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies","volume":"11","author":"Van De Donk","year":"2024","journal-title":"Lancet Haematol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41420-023-01765-8","article-title":"What happens to regulatory t cells in multiple myeloma","volume":"9","author":"Chen","year":"2023","journal-title":"Cell Death Discov"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active t cell-redirecting bispecific antibody against b-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-026-02113-7","article-title":"Single-cell profiling reveals mif-mediated immune evasion and cd8\u2009+\u2009t cell exhaustion in relapsed multiple myeloma","volume":"26","author":"Ma","year":"2026","journal-title":"Clin Exp Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"Car t cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell rna sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007217","article-title":"Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level","volume":"6","author":"Schinke","year":"2022","journal-title":"Blood Adv"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/Fimmu.2019.01596","article-title":"Mass cytometry discovers two discrete subsets of Cd39-Treg which discriminate Mgus from multiple myeloma","volume":"10","author":"Marsh-Wakefield","year":"2019","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/Fimmu.2021.699895","article-title":"Tigit, the next step towards successful combination immune checkpoint therapy in cancer","volume":"12","author":"Ge","year":"2021","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/J.Intimp.2023.110852","article-title":"Unravelling the imbalanced Th17-like cell differentiation by single-cell Rna sequencing in multiple myeloma","volume":"124","author":"Wan","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/Pnas.1822001116","article-title":"Pd-1+ regulatory T cells amplified by Pd-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3390\/Cancers13010048","article-title":"Hyper-progressive disease: the potential role and consequences of T-regulatory cells foiling anti-Pd-1 cancer immunotherapy","volume":"13","author":"Tay","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B106","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/S12935-018-0687-8","article-title":"Increased activated regulatory T cell subsets and aging Treg-like cells in multiple myeloma and monoclonal gammopathy of undetermined significance: a case control study","volume":"18","author":"Wang","year":"2018","journal-title":"Cancer Cell Int"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/Fimmu.2025.1595613","article-title":"Significance of the peripheral blood Treg\/Th17 ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma and its correlation with 1q21 gain\/amplification","volume":"16","author":"Wen","year":"2025","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/Fcell.2021.737880","article-title":"Bone marrow regulatory T cells are a unique population, supported by niche-specific cytokines and plasmacytoid dendritic cells, and required for chronic graft-versus-host disease control","volume":"9","author":"Nicholls","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/Fimmu.2024.1415102","article-title":"Cd39 delineates chimeric antigen receptor regulatory T cell subsets with distinct cytotoxic & regulatory functions against human islets","volume":"15","author":"Wu","year":"2024","journal-title":"Front Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/S12943-024-02156-Y","article-title":"Regulatory T cells in immune checkpoint blockade antitumor therapy","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/Cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"key":"B112","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/S00262-012-1308-3","article-title":"Lenalidomide enhances anti-myeloma cellular immunity","volume":"62","author":"Luptakova","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1111\/Cei.12343","article-title":"Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients","volume":"177","author":"Busch","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/Blood-2008-11-190421","article-title":"Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused Nk cells","volume":"113","author":"Lundqvist","year":"2009","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.Crc-24-0638","article-title":"Safety and antitumor activity of a novel Acd25 Treg depleter Rg6292 as a single agent and in combination with atezolizumab in patients with solid tumors","volume":"5","author":"Gambardella","year":"2025","journal-title":"Cancer Res Commun"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/S43018-020-00133-0","article-title":"Cd25-T(Reg)-depleting antibodies preserving Il-2 signaling on effector T cells enhance effector activation and antitumor immunity","volume":"1","author":"Solomon","year":"2020","journal-title":"Nat Cancer"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-25-0101","article-title":"Pf-08046032: a novel, investigational Cd25-directed antibody-drug conjugate optimized for selective depletion of regulatory T cells in advanced Malignant tumors","volume":"24","author":"Abdelhamed","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1056\/Nejmra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.09.24313308","article-title":"Fc-enhanced anti-Ctla-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer","author":"Ager","year":"2025","journal-title":"Medrxiv"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1073\/Pnas.2114282119","article-title":"Ccr8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory","volume":"119","author":"Kidani","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/S41375-021-01301-6","article-title":"Targeting Lag3\/Gal-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma","volume":"36","author":"Bae","year":"2022","journal-title":"Leukemia"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/Blood-2005-09-3671","article-title":"In vivo peripheral expansion of naive Cd4+Cd25high Foxp3+ regulatory T cells in patients with multiple myeloma","volume":"107","author":"Beyer","year":"2006","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.4049\/Jimmunol.181.5.3714","article-title":"Increased regulatory versus effector T cell development is associated with thymus atrophy in mouse models of multiple myeloma","volume":"181","author":"Laronne-Bar-On","year":"2008","journal-title":"J Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1111\/J.1365-2141.2008.07530.X","article-title":"Cd4(+)Cd25(+)Foxp3(+) regulatory T cells are increased whilst Cd3(+)Cd4(-)Cd8(-)Alphabetatcr(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden","volume":"144","author":"Feyler","year":"2009","journal-title":"Br J Haematol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/J.1365-3083.2010.02463.X","article-title":"Increased level of both Cd4+Foxp3+ regulatory T cells and Cd14+Hla-Dr-\/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma","volume":"72","author":"Brimnes","year":"2010","journal-title":"Scand J Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/J.Leukres.2010.11.010","article-title":"Significantly reduced regulatory T cell population in patients with untreated multiple myeloma","volume":"35","author":"Gupta","year":"2011","journal-title":"Leuk Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1371\/Journal.Pone.0047077","article-title":"Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma","volume":"7","author":"Muthu Raja","year":"2012","journal-title":"PloS One"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/Bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/Cyto.B.21109","article-title":"Flow cytometry-based enumeration and functional characterization of Cd8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment","volume":"86","author":"Raja","year":"2014","journal-title":"Cytom B Clin Cytom"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-14-62","article-title":"Relationship between abnormal osteoblasts and cellular immunity in multiple myeloma","volume":"14","author":"Fu","year":"2014","journal-title":"Cancer Cell Int"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/S00262-014-1589-9","article-title":"Foxp3 and Ctla4 overexpression in multiple myeloma bone marrow as a sign of accumulation of Cd4(+) T regulatory cells","volume":"63","author":"Braga","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B132","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/Ejh.12481","article-title":"Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells in vitro","volume":"95","author":"Frassanito","year":"2015","journal-title":"Eur J Haematol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1007\/S10753-014-9980-4","article-title":"The alteration and clinical significance of Th1\/Th2\/Th17\/Treg cells in patients with multiple myeloma","volume":"38","author":"Feng","year":"2015","journal-title":"Inflammation"},{"key":"B134","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/J.Bbrc.2016.10.098","article-title":"Characterization of \u0393\u03b4 regulatory T cells from peripheral blood in patients with multiple myeloma","volume":"480","author":"Ma","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1579324","article-title":"Evaluating the role of Tregs in the progression of multiple myeloma","volume":"60","author":"Lad","year":"2019","journal-title":"Leuk Lymph"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-1714","article-title":"Marrow-infiltrating regulatory T cells correlate with the presence of dysfunctional Cd4+Pd-1+ cells and inferior survival in patients with newly diagnosed multiple myeloma","volume":"26","author":"Alrasheed","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3390\/Ijms22179298","article-title":"Deregulated expression of immune checkpoints on circulating Cd4 T cells may complicate clinical outcome and response to treatment with checkpoint inhibitors in multiple myeloma patients","volume":"22","author":"Kulikowska De Na\u0142\u0119cz","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1182\/Blood-2010-05-283895","article-title":"A novel role of Il-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma","volume":"116","author":"Noonan","year":"2010","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1002\/Cam4.70980","article-title":"Tregs at diagnosis as a potential biomarker for predicting high-risk functionality in newly diagnosed multiple myeloma","volume":"14","author":"Zhou","year":"2025","journal-title":"Cancer Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1830089\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:07:39Z","timestamp":1777442859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1830089\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":139,"alternative-id":["10.3389\/fimmu.2026.1830089"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1830089","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"1830089"}}